Avid Bioservices Inc (CDMO)

[hutschi]

Phosphatidylserine-exposing cells contribute to the hypercoagulable state in patients with multiple myeloma.
Guo L1, Tong D1, Yu M1, Zhang Y1, Li T1, Wang C1, Zhou P2, Jin J2, Li B3, Liu Y3, Liu R4, Novakovic VA5, Dong Z6, Tian Y6, Kou J4, Bi Y6, Zhou J1, Shi J1.
Author information
Abstract
Multiple myeloma (MM) is characterized by an increased incidence of thromboembolic events, particularly when treated with immunomodulatory drugs (IMiDs) in combination with dexamethasone. The optimal prophylactic strategy to prevent the hypercoagulable state of patients with MM is still debated. The aim of the current study was to investigate the definitive role of phosphatidylserine (PS) in supporting procoagulant activity (PCA) in patients with MM. Patients with MM (n=20) and healthy subjects (n=15) were recruited for the present study. PS analyses were performed by flow cytometry and confocal microscopy. The PCA was evaluated by clotting time, purified coagulation complex assays and fibrin production assays. The percentage of PS+ blood cells was significantly higher in patients with MM than in healthy subjects. Additionally, the patient serum induced more PS exposure on endothelial cells (ECs) in vitro than serum from healthy subjects. Isolated blood cells from patients with MM and ECs cultured with patient serum in vitro demonstrated significantly shortened coagulation time, greatly intrinsic/extrinsic factor Xa generation and increased thrombin formation. In addition, the levels of PS+ erythrocytes, platelets, leukocytes, and ECs incubated with IMiDs and dexamethasone were higher than with IMiDs alone. The findings support the hypothesis that increased PS exposure on blood cells and ECs participates in the hypercoagulable state in patients with MM. Thus, blocking PS may be a novel therapeutic target for the prevention of thrombosis in these patients.

https://www.ncbi.nlm.nih.gov/pubmed/29620266

Boston and China hmmmmm..... Oncologie???